# Adoram Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adoram-therapeutics

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.adoram.ch
- Total disclosed funding: $0.1M
- Latest round: Seed (Oct 25, 2024)
- Investors on record: 1

## About

Founded in 2022 by co-founders David Pejoski, Hesham Hamed, and Leonardo Scapozza and based in Geneva, Switzerland, Adoram Therapeutics SA is engaged in developing allosteric molecular modes of action-based therapies to treat patients with cancer. In February 2025, Adoram Therapeutics SA raised an undisclosed amount of pre-seed funding from Ipalmetrix, FONGIT, and an individual investor. Adoram Therapeutics offers A2AR NAM (negative allosteric modulator of the adenosine 2A receptor), designed to augment the anti-tumour immune response in patients suffering from various solid tumours. This product is in the preclinical testing stage. Additionally, the company offers A2AR PAM (positive allosteric modulator), a preclinical asset in the development of inflammatory and autoimmune disorders. The company’s targeted therapeutic solutions primarily serve oncology patients who are unresponsive to existing immunotherapies or lack access to complex therapies. The company will use the February 2025 funding to accelerate the development of its small molecule drugs for cancer immunotherapy and inflammatory conditions, and to expand its pipeline through collaborations with co-development partners.

## Funding rounds

- Seed, Oct 25, 2024, $0.1M — FONGIT

## Investors

- FONGIT (https://capitalatlas.ai/funds/fongit) — Seed